|
| 复方鳖甲软肝片对非酒精性脂肪肝病肝纤维化的疗效评价 |
| Evaluation of the effectiveness of Biejia-Ruangan compound on liver fibrosis in non-alcoholic fatty liver disease |
| 投稿时间：2024-01-29 修订日期：2024-03-23 |
| DOI： |
| 中文关键词: 非酒精性脂肪性肝病 肝纤维化 中药 复方鳖甲软肝片 |
| 英文关键词: NAFLD Liver fibrosis traditional Chinese medicine Biejia-Ruangan compound |
| 基金项目: |
|
| 摘要点击次数: 24 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 评价复方鳖甲软肝片（BRC）对于非酒精性脂肪肝病（NAFLD）肝纤维化的治疗效果。方法 回顾性纳入NAFLD患者，根据治疗方式分为采用指南推荐的保肝治疗6个月（对照组）和指南推荐的保肝治疗联合BRC（2.0g，口服，3次/日）6个月（治疗组），以治疗6个月后肝纤维化改善率[肝脏纤维化-4指数（FIB-4）、天冬氨酸氨基转移酶和血小板比值指数（APRI）及肝弹性检测（LSM）下降20%分别进行分析]为评价标准，并通过多因素分析寻找影响结局的相关因素。结果 临床回顾性研究纳入144例NAFLD患者，年龄中位数为50岁，男性占40.3%。治疗组肝纤维化改善率分别为75.6%（FIB-4）、69.9%（APRI）及88.6%（LSM），显著高于对照组的24.4%、30.1%及11.4% （P<0.001）。两组患者治疗前后血清TC和TG水平改变无统计学意义（P均>0.05）。Logistic回归结果显示BRC治疗是肝纤维化的保护因素（以FIB-4为评价指标：OR=4.04, 95%CI 1.60-10.23, P=0.003；以APRI为评价指标：OR=4.76, 95% CI 2.04-11.10, P<0.001；以LSM为评价指标：OR=15.32, 95%CI 4.93-47.65, P<0.001）。结论 复方鳖甲软肝片可显著改善非酒精性脂肪性肝病的无创肝纤维化指数。 |
| 英文摘要: |
| Objective To evaluate the therapeutic effectiveness of Biejia-Ruangan compound (BRC) in non-alcoholic fatty liver disease (NAFLD). Methods NAFLD patients were retrospectively enrolled and divided into only liver protection treatment recommended by the guidelines (control group) or the liver protection treatment recommended by the guidelines combining BRC (treatment group). The improvement rates of liver fibrosis were evaluated based on the 20% reduction in fibrosis-4 (FIB-4), Aspartate Aminotransferase to Platelet Ratio Index (APRI), or Liver Stiffness Measurement (LSM) after 6-month treatment, respectively. Multivariate analysis was conducted to explore factors associated with the improvement of liver fibrosis. Results 144 NAFLD patients were enrolled retrospectively. The median age was 50 years old and 40.3% of patients were male. The improvement rates of liver fibrosis in BRC group were 75.6% (FIB-4), 69.9% (APRI) and 88.6% (LSM), which were significantly higher than the control group (FIB-4: 24.4%, APRI: 30.1% and LSM: 11.4%, P<0.001) after 6-month treatment. The logistic regression analysis showed that BRC treatment was a protective factor for liver fibrosis (FIB-4: OR=4.04, 95% CI 1.60-10.23, P=0.003; APRI: OR=4.76, 95% CI 2.04-11.10, P<0.001; LSM: OR=15.32, 95% CI 4.93-47.65, P<0.001). Conclusion Biejia-Ruangan compound could significantly improve the value of noninvasive liver fibrosis in NAFLD. |
|
HTML
下载PDF阅读器 |
| 关闭 |
|
|
|